LXRX Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lexicon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.56 |
| 52 Week High | US$3.73 |
| 52 Week Low | US$0.92 |
| Beta | 1.36 |
| 11 Month Change | -2.50% |
| 3 Month Change | -17.46% |
| 1 Year Change | -9.83% |
| 33 Year Change | -57.61% |
| 5 Year Change | 7.59% |
| Change since IPO | -98.81% |
Recent News & Updates
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Recent updates
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Apr 25Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?
Jan 04Shareholder Returns
| LXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -30.7% | -4.9% | -5.7% |
| 1Y | -9.8% | 11.5% | 14.1% |
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 13.1% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LXRX's share price has been volatile over the past 3 months.
Volatility Over Time: LXRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 285 | Mike Exton | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Fundamentals Summary
| LXRX fundamental statistics | |
|---|---|
| Market cap | US$592.85m |
| Earnings (TTM) | -US$202.11m |
| Revenue (TTM) | US$3.64m |
154.9x
P/S Ratio-2.8x
P/E RatioIs LXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXRX income statement (TTM) | |
|---|---|
| Revenue | US$3.64m |
| Cost of Revenue | US$64.61m |
| Gross Profit | -US$60.97m |
| Other Expenses | US$141.14m |
| Earnings | -US$202.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | -1,674.49% |
| Net Profit Margin | -5,550.87% |
| Debt/Equity Ratio | 41.5% |
How did LXRX perform over the long term?
See historical performance and comparison